BRAF and pleomorphic xanthoastrocytoma: In an ongoing Phase II clinical trial, PLGG-MEKTRIC (NCT05180825), the MEK inhibitor trametinib (MekinistTM) is being compared to standard chemotherapy with vinblastine over 18 courses of 4 weeks each in pediatric low-grade glioma and mixed glioneuronal tumors, including pleomorphic xanthoastrocytoma (PXA) without BRAF V600E mutation or NF1 correlation.